Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2752 - Comparison of PARPi with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: a network meta-analysis

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Cytotoxic Therapy

Tumour Site

Ovarian Cancer

Presenters

Yan Feng

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

Y.L. Feng, J.H. Liu, H. Huang, C. ZHANG, T. Wan, C.J. Tong, T. Deng, H. Tu, Y.W. Huang, G. Liu, Q.D. Huang, Z.M. Liu

Author affiliations

  • Gynecologic Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
More

Resources

Abstract 2752

Background

Recent targeted therapies such as poly-ADP ribose polymerase inhibitors (PARPi) and angiogenesis inhibitors (AI) are known to ease burden and recurrence of ovarian cancer. This network meta-analysis conducted an indirect treatment comparison between PARPi, AI and chemotherapeutic agents (CTA) in terms of clinical efficacy and safety as maintenance therapy in ovarian cancer patients irrespective of BRCA status.

Methods

We searched relevant sources (PubMed, EMBASE) to identify randomized controlled trials in ovarian cancer patients undergoing maintenance therapy. Studies assessing efficacy and safety of PARPi (n = 4), AIs (n = 12), CTA (n = 8) with placebo were analyzed. Primary outcome included progression free survival (PFS), safety and tolerability were secondary outcomes. A network meta-analysis to compare 3 drug classes was performed using statistical software R.

Results

PARPi [Hazard Ratio (HR) =0.64; 95% Credible Intervals (CrI) =0.55-0.73] and AI (HR = 0.87; 95% CrI=0.81-0.93) showed significant improvement in PFS compared to placebo but not CTA (HR = 1.00; 95% CrI=0.86-1.15, Table). PARPi showed significant improvement in PFS compared to AI (HR = 0.73; 95% CrI=0.63-0.86) and CTA (HR = 0.64; 95% CrI=0.52-0.78). Adverse events (AEs) leading to treatment discontinuation and dose reduction were lower in PARPi [Incidence Rate Ratio (IRR) =1.64; CrI=0.84-3.19, IRR=0.73, 95% CrI=0.50-1.06 respectively] compared to AI, but not significant.Table: 976P

Comparison of PFS data across different therapies

TreatmentAICTAPARPiPlacebo
AI-1.14 (0.98, 1.35)0.73 (0.63, 0.86)1.15 (1.07, 1.24)
CTA0.87 (0.74, 1.02)-0.64 (0.52, 0.78)1.00 (0.87, 1.16)
PARPi1.37 (1.16, 1.6)1.57 (1.28, 1.92)-1.57 (1.36, 1.81)
Placebo0.87 (0.81, 0.93)1.00 (0.86, 1.15)0.64 (0.55, 0.73)-

AI angiogenesis inhibitors; CTA chemotherapeutic agents; PARPi poly ADP ribose polymerase inhibitors.

Conclusions

PARPi as maintenance treatment improved PFS in ovarian cancer and was relatively safer in terms of AEs caused implications when compared to other therapies. This network meta-analysis provides valuable evidence and significant insights in treatment of ovarian cancer.

Clinical trial identification

Legal entity responsible for the study

Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou.

Funding

AstraZeneca.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.